Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 29, 2014. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 561,700 Ordinary Shares of 25 pence each.
- Purchase Date: May 29, 2014.
- Price Range: Highest price paid was 1,625.00 pence per share; lowest price paid was 1,606.00 pence per share.
- Treasury Holdings (Settled): 493,929,462 shares (9.23% of total issued share capital).
- Treasury Holdings (Including Unsettled): 495,272,414 shares (10.20% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,856,715,301 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 561,700 shares. Consequently, the percentage of total voting rights held in treasury increased to 10.20% when including unsettled purchases. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase transaction compliant with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (493,929,462 settled) against the company's latest annual report.
- Confirm the calculation of total voting rights (10.20% held in treasury including unsettled shares).
- Check the price paid per share (1,606.00 to 1,625.00 pence) against market trading data for May 29, 2014.
- Review the remaining authorized share buyback limit, as this filing only reports a single transaction.